Grading allergic ocular disease

Article

Research published online ahead of print by Graefe's Archive for Clinical and Experimental Ophthalmology, has revealed that allergic ocular diseases can be classified and clinically evaluated using a grading system.

Research published online ahead of print by Graefe's Archive for Clinical and Experimental Ophthalmology, has revealed that allergic ocular diseases can be classified and clinically evaluated using a grading system.

Eiichi Uchio and colleagues from Fukuoka University School of Medicine, Japan created a number of criteria for classifying and clinically evaluating the severity of allergic ocular diseases. They then evaluated the effectiveness of the criteria in the diagnosis of 1,079 patients.

The researchers diagnosed and classified allergic conjunctivitis, atopic keratoconjunctivitis and vernal keratoconjunctivitis based on local and systemic clinical findings. Ten objective conjunctival, limbal and corneal lesion findings were graded on a four-point scale. The total score was used as the clinical score, with a highest value of 30.

Of the 1,079 subjects, 876 (81.2%) were diagnosed with seasonal allergic conjunctivitis, 115 (10.7%) with perennial allergic conjunctivitis, 47 (4.4%) with atopic keratoconjunctivitis and 41 (3.8%) with vernal keratoconjunctivitis. The total clinical scores were 1.54 in seasonal allergic conjunctivitis, 2.13 in perennial allergic conjunctivitis, 3.72 in atopic keratoconjunctivitis and 12.68 in vernal keratoconjunctivitis.

The authors concluded that re-evaluation of allergic ocular disease is necessary for building future strategies for its treatment.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.